Drug Profile
Mogamulizumab - Kyowa Kirin
Alternative Names: AMG 761; KW-0761; Mogamulizumab-kpkc; PoteligeoLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Developer Amgen; Bristol-Myers Squibb; Kyowa Hakko; Kyowa Hakko Kirin; Kyowa Kirin; Memorial Sloan-Kettering Cancer Center; Ono Pharmaceutical
- Class Antiasthmatics; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR4 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Adult T-cell leukaemia-lymphoma; Cutaneous T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome
- No development reported Non-small cell lung cancer
- Discontinued Asthma; Hypersensitivity; Solid tumours; Spinal cord disorders
Most Recent Events
- 30 Sep 2023 Preregistration for Mycosis fungoides in Singapore, Taiwan (IV) before September 2023 (Kyowa Kirin pipeline, February 2024)
- 30 Sep 2023 Preregistration for Sezary syndrome in Singapore, Taiwan (IV) before September 2023 (Kyowa Kirin pipeline, February 2024)
- 30 Sep 2023 Registered for Mycosis fungoides in Kuwait (IV) (before September 2023)